High-throughput, multi-parametric analysis accelerates antibody discovery workflows

Antibody discovery programs rely on high-throughput technologies to quickly identify candidates with therapeutic potential. Evaluating antibodies for the desired therapeutic mechanism of action is an important part of the antibody screening strategy. For instance, binding and rapid internalization are desirable properties for antibody-drug conjugates, where cytotoxic agents are delivered into cancer cells. In contrast, antibody internalization is less important when the goal is to induce antibody-dependent cell-mediated cytotoxicity (ADCC) or antibody-dependent cellular phagocytosis (ADCP), which depend on cell receptors binding to the Fc portions of antibodies to induce an effector response.

In this White Paper, we present the unique benefits of iQue® advanced high-throughput flow cytometry in the antibody discovery workflow. Using predominantly studies with Her2-positive and CD20-positive cell models, and anti-Her2 and anti-CD20 mAbs, we show how this technology provides quantitative data on binding, antibody internalization, ADCP, ADCC and T-cell activation.